Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2019

01-02-2019 | Original Article

Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn’s Disease

Authors: James R. Irwin, Emma Ferguson, Lisa A. Simms, Katherine Hanigan, James D. Doecke, Daman Langguth, Ashley Arnott, Graham Radford-Smith

Published in: Digestive Diseases and Sciences | Issue 2/2019

Login to get access

Abstract

Background and Aims

Patients with inflammatory bowel disease (IBD) often have subjective symptoms for months or years prior to their diagnosis. Blood tests taken prior to diagnosis may provide objective evidence of duration of pre-diagnosis disease. We aim to describe the pre-diagnosis laboratory pattern of patients with IBD.

Methods

A total of 838 patients diagnosed with IBD between 01/01/1996 and 01/03/2014, with pre-diagnosis laboratory testing available, contributed data for analysis. C-reactive protein, erythrocyte sedimentation rate, hemoglobin level, mean cell volume (MCV) platelet count, white blood cell count, neutrophil count, albumin level, ferritin level, serum iron level, alanine transaminase level, and fecal calprotectin were examined in the 24 months leading up to diagnosis and compared to baseline data taken between 24 and 36 months prior to diagnosis.

Results

For patients with Crohn’s disease, a significant drop in serum albumin and MCV levels and a significant rise in platelet count were observed between 115 and 385 days prior to diagnosis (p < 0.01, two-tailed t test). For patients with ulcerative colitis, a significant change in albumin level, MCV, hemoglobin level, platelet count, and serum iron level was observed at diagnosis (p < 0.01, two-tailed t test) but was not detectable before.

Conclusions

These data provide objective evidence of duration of delay between disease onset and diagnosis in a cohort of patients with IBD. Expediting diagnostic testing in patients presenting with symptoms consistent with IBD, who also have abnormal laboratory results, may reduce diagnostic delay, speed access to therapy, and improve clinical outcomes.
Literature
1.
go back to reference Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.CrossRefPubMed Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.CrossRefPubMed
4.
go back to reference Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: A prospective evaluation. Gastrointest Endosc. 1983;29:195–197.CrossRefPubMed Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: A prospective evaluation. Gastrointest Endosc. 1983;29:195–197.CrossRefPubMed
5.
go back to reference Schumacher G, Sandstedt B, Kollberg B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Clinical findings and early diagnosis. Scand J Gastroenterol. 1994;29:265–274.CrossRefPubMed Schumacher G, Sandstedt B, Kollberg B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Clinical findings and early diagnosis. Scand J Gastroenterol. 1994;29:265–274.CrossRefPubMed
14.
go back to reference Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18:1282–1284.PubMed Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18:1282–1284.PubMed
15.
go back to reference del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 1988;31:1239–1244.CrossRefPubMed del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 1988;31:1239–1244.CrossRefPubMed
16.
go back to reference Jónsson T, Thorsteinsson J, Kolbeinsson A, Jónasdóttir E, Sigfússon N, Valdimarsson H. Population study of the importance of rheumatoid factor isotypes in adults. Ann Rheum Dis. 1992;51:863–868.CrossRefPubMedPubMedCentral Jónsson T, Thorsteinsson J, Kolbeinsson A, Jónasdóttir E, Sigfússon N, Valdimarsson H. Population study of the importance of rheumatoid factor isotypes in adults. Ann Rheum Dis. 1992;51:863–868.CrossRefPubMedPubMedCentral
17.
go back to reference Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun. 1996;9:379–383.CrossRefPubMed Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun. 1996;9:379–383.CrossRefPubMed
18.
go back to reference R Core Team. R: A Language and Environment for Statistical Computing, R version 3.4.4. Vienna, Austria: R Foundation for Statistical Computing; 2018. https://www.R-project.org/. Accessed 12 Nov 2018. R Core Team. R: A Language and Environment for Statistical Computing, R version 3.4.4. Vienna, Austria: R Foundation for Statistical Computing; 2018. https://​www.​R-project.​org/​. Accessed 12 Nov 2018.
21.
go back to reference Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale: L. Erlbaum Associates; 1988. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale: L. Erlbaum Associates; 1988.
31.
go back to reference Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr. 2004;80:1342–1352.CrossRefPubMed Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr. 2004;80:1342–1352.CrossRefPubMed
33.
go back to reference Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–813.CrossRefPubMedPubMedCentral Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–813.CrossRefPubMedPubMedCentral
34.
go back to reference Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn’s disease. Scand J Gastroenterol. 2008;43:961–966.CrossRefPubMed Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn’s disease. Scand J Gastroenterol. 2008;43:961–966.CrossRefPubMed
Metadata
Title
Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn’s Disease
Authors
James R. Irwin
Emma Ferguson
Lisa A. Simms
Katherine Hanigan
James D. Doecke
Daman Langguth
Ashley Arnott
Graham Radford-Smith
Publication date
01-02-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5357-0

Other articles of this Issue 2/2019

Digestive Diseases and Sciences 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.